Bao-jian Wu

Dr. Bao-jian Wu


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShuai Wang
Shuai Wang
YLYanke Lin
Yanke Lin
XYXue Yuan
Xue Yuan
FLFeng Li
Feng Li
LGLianxia Guo
Lianxia Guo
BWBao-jian Wu
Bao-jian Wu
The roles of Rev-erbα and circadian clock in colonic inflammation remain unclarified. Here we show colon clock genes (including Rev-erbα) are dysregulated in mice with DSS-induced colitis. In turn, disruption of the circadian clock exacerbates experimental colitis. Rev-erbα-deficient mice are more sensitive to DSS-induced colitis, supporting a critical role of Rev-erbα in disease development. Further, Rev-erbα ablation causes activation of Nlrp3 inflammasome in mice. Cell-based experiments reveal Rev-erbα inactivates Nlrp3 inflammasome mainly at the priming stage. Rev-erbα directly represses Nlrp3 transcription through specific binding to the promoter region. Additionally, Rev-erbα represses p65 transcription and indirectly repressed Nlrp3 via the NF-κB pathway. Interestingly, Rev-erbα activation in wild-type mice by SR9009 attenuates DSS-induced colitis, whereas the protective effects are lost in Nlrp3−/− and Rev-erbα−/− mice. Taken together, Rev-erbα regulates experimental colitis through its repressive action on the NF-κB/Nlrp3 axis. Targeting Rev-erbα may represent a promising approach for prevention and management of colitis.

1 December 2012 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
BWBao-jian Wu
Bao-jian Wu
DDDong Dong
Dong Dong

1 August 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DDDong Dong
Dong Dong
DYDeguang Yang
Deguang Yang
LLLuomin Lin
Luomin Lin
SWShuai Wang
Shuai Wang
BWBao-jian Wu
Bao-jian Wu

1 January 2020 in Theranostics
Verified
Journal Article
Open access
SWShuai Wang
Shuai Wang
FLFeng Li
Feng Li
YLYanke Lin
Yanke Lin
BWBao-jian Wu
Bao-jian Wu
REV-ERBα (NR1D1) is a circadian clock component that functions as a transcriptional repressor. Due to its role in direct modulation of metabolic genes, REV-ERBα is regarded as an integrator of cell metabolism with circadian clock. Accordingly, REV-ERBα is first proposed as a drug target for treating sleep disorders and metabolic syndromes (e.g., dyslipidaemia, hyperglycaemia and obesity). Recent years of studies uncover a rather broad role of REV-ERBα in pathological conditions including local inflammatory diseases, heart failure and cancers. Moreover, REV-ERBα is involved in regulation of circadian drug metabolism that has implications in chronopharmacology. In the meantime, recent years have witnessed discovery of an array of new REV-ERBα ligands most of which have pharmacological activities in vivo. In this article, we review the regulatory role of REV-ERBα in various types of diseases and discuss the underlying mechanisms. We also describe the newly discovered ligands and the old ones together with their targeting potential. Despite well-established pharmacological effects of REV-ERBα ligands in animals (preclinical studies), no progress has been made regarding their translation to clinical trials. This implies certain challenges associated with drug development of REV-ERBα ligands. In particular, we discuss the potential challenges related to drug safety (or adverse effects) and bioavailability. For new drug development, it is advocated that REV-ERBα should be targeted to treat local diseases and a targeting drug should be locally distributed, avoiding the adverse effects on other tissues.

1 January 2022 in Theranostics
Verified
Journal Article
Open access
SWShuai Wang
Shuai Wang
YLYanke Lin
Yanke Lin
LGLu Gao
Lu Gao
ZYZemin Yang
Zemin Yang
JLJingpan Lin
Jingpan Lin
BWBao-jian Wu
Bao-jian Wu
While growing evidence suggests that circadian clock and obesity are intertwined, the underlying mechanism is poorly understood. Here, we investigate how circadian clock is linked to obesity.

1 January 2019 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WDWenji Deng
Wenji Deng
HWHuan Wang
Huan Wang
BWBao-jian Wu
Bao-jian Wu
Xingwang ZhangXingwang Zhang
Xingwang Zhang
Diabetes mellitus (DM) remains a great challenge in treatment due to pathological complexity. It has been proven that phytomedicines and natural medicines have prominent antidiabetic effects. This work aimed to develop selenium-layered nanoparticles (SeNPs) for oral delivery of mulberry leaf and Pueraria Lobata extracts (MPE), a group of phytomedicines with significant hypoglycemic activities, to achieve a synergic antidiabetic effect. MPE-loaded SeNPs (MPE-SeNPs) were prepared through a solvent diffusion/in situ reduction technique and characterized by particle size, ζ potential, morphology, entrapment efficiency (EE) and drug loading (DL). The resulting MPE-SeNPs were 120 nm around in particle size with EE of 89.38% for rutin and 90.59% for puerarin, two marker components in MPE. MPE-SeNPs exhibited a slow drug release and good physiological stability in the simulated digestive fluid. After oral administration, MPE-SeNPs produced significant hypoglycemic effects both in the normal and diabetic rats. Ex vivo intestinal imaging and cellular examinations demonstrated that MPE-SeNPs were provided with outstanding intestinal permeability and transepithelial transport aptness. It was also revealed that MPE-SeNPs could alleviate the oxidative stress, improve the pancreatic function, and promote the glucose utilization by adipocytes. Our study provides new insight into the use of integrative nanomedicine containing phytomedicines and selenium for DM treatment.